vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Goosehead Insurance, Inc. (GSHD). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $93.1M, roughly 1.8× Goosehead Insurance, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 23.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 9.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Goosehead Insurance is a U.S.-based personal lines insurance agency that offers a wide range of coverage products including auto, home, renters, flood, and specialty insurance. It partners with hundreds of insurance carriers to provide clients with tailored, cost-effective coverage options, operating via corporate locations and a national franchise network for independent agents.
ESPR vs GSHD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $93.1M |
| Net Profit | — | $8.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 16.1% |
| Net Margin | — | 8.6% |
| Revenue YoY | 143.7% | 23.1% |
| Net Profit YoY | — | 204.0% |
| EPS (diluted) | $0.32 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $93.1M | ||
| Q4 25 | $168.4M | $105.3M | ||
| Q3 25 | $87.3M | $90.4M | ||
| Q2 25 | $82.4M | $94.0M | ||
| Q1 25 | $65.0M | $75.6M | ||
| Q4 24 | $69.1M | $93.9M | ||
| Q3 24 | $51.6M | $78.0M | ||
| Q2 24 | $73.8M | $78.1M |
| Q1 26 | — | $8.0M | ||
| Q4 25 | — | $12.4M | ||
| Q3 25 | $-31.3M | $7.9M | ||
| Q2 25 | $-12.7M | $5.2M | ||
| Q1 25 | $-40.5M | $2.3M | ||
| Q4 24 | — | $14.9M | ||
| Q3 24 | $-29.5M | $7.6M | ||
| Q2 24 | $-61.9M | $6.2M |
| Q1 26 | — | 16.1% | ||
| Q4 25 | 50.6% | 29.4% | ||
| Q3 25 | -11.4% | 23.5% | ||
| Q2 25 | 8.6% | 16.7% | ||
| Q1 25 | -34.0% | 8.8% | ||
| Q4 24 | -6.4% | 29.7% | ||
| Q3 24 | -31.0% | 21.1% | ||
| Q2 24 | 3.5% | 19.7% |
| Q1 26 | — | 8.6% | ||
| Q4 25 | — | 11.8% | ||
| Q3 25 | -35.9% | 8.7% | ||
| Q2 25 | -15.4% | 5.5% | ||
| Q1 25 | -62.2% | 3.1% | ||
| Q4 24 | — | 15.8% | ||
| Q3 24 | -57.2% | 9.7% | ||
| Q2 24 | -83.9% | 7.9% |
| Q1 26 | — | $0.19 | ||
| Q4 25 | $0.32 | $0.48 | ||
| Q3 25 | $-0.16 | $0.29 | ||
| Q2 25 | $-0.06 | $0.18 | ||
| Q1 25 | $-0.21 | $0.09 | ||
| Q4 24 | $-0.14 | $0.58 | ||
| Q3 24 | $-0.15 | $0.29 | ||
| Q2 24 | $-0.33 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $25.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $-121.3M |
| Total Assets | $465.9M | $392.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $25.7M | ||
| Q4 25 | $167.9M | $34.4M | ||
| Q3 25 | $92.4M | $51.6M | ||
| Q2 25 | $86.1M | $92.4M | ||
| Q1 25 | $114.6M | $70.2M | ||
| Q4 24 | $144.8M | $54.3M | ||
| Q3 24 | $144.7M | $47.5M | ||
| Q2 24 | $189.3M | $23.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $289.5M | ||
| Q3 25 | — | $290.0M | ||
| Q2 25 | — | $289.8M | ||
| Q1 25 | — | $290.3M | ||
| Q4 24 | — | $82.3M | ||
| Q3 24 | — | $84.6M | ||
| Q2 24 | — | $87.0M |
| Q1 26 | — | $-121.3M | ||
| Q4 25 | $-302.0M | $-95.5M | ||
| Q3 25 | $-451.4M | $-105.0M | ||
| Q2 25 | $-433.5M | $-78.6M | ||
| Q1 25 | $-426.2M | $-88.5M | ||
| Q4 24 | $-388.7M | $43.9M | ||
| Q3 24 | $-370.2M | $58.3M | ||
| Q2 24 | $-344.2M | $39.8M |
| Q1 26 | — | $392.8M | ||
| Q4 25 | $465.9M | $414.9M | ||
| Q3 25 | $364.0M | $403.6M | ||
| Q2 25 | $347.1M | $436.6M | ||
| Q1 25 | $324.0M | $412.6M | ||
| Q4 24 | $343.8M | $397.7M | ||
| Q3 24 | $314.1M | $358.1M | ||
| Q2 24 | $352.3M | $338.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.87× | ||
| Q3 24 | — | 1.45× | ||
| Q2 24 | — | 2.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $91.8M | ||
| Q3 25 | $-4.3M | $24.2M | ||
| Q2 25 | $-31.4M | $28.9M | ||
| Q1 25 | $-22.6M | $15.5M | ||
| Q4 24 | $-35.0M | $71.5M | ||
| Q3 24 | $-35.3M | $28.1M | ||
| Q2 24 | $-7.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $86.1M | ||
| Q3 25 | — | $23.7M | ||
| Q2 25 | — | $27.2M | ||
| Q1 25 | — | $14.9M | ||
| Q4 24 | — | $70.6M | ||
| Q3 24 | $-35.5M | $28.0M | ||
| Q2 24 | $-7.3M | $18.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 81.8% | ||
| Q3 25 | — | 26.2% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 75.1% | ||
| Q3 24 | -68.7% | 35.9% | ||
| Q2 24 | -9.9% | 23.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.4% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 1.0% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 7.38× | ||
| Q3 25 | — | 3.06× | ||
| Q2 25 | — | 5.61× | ||
| Q1 25 | — | 6.61× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 3.72× | ||
| Q2 24 | — | 3.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
GSHD
| Renewal Royalty Fees (2) | $43.6M | 47% |
| Renewal Commissions (1) | $18.2M | 20% |
| Contingent Commissions (1) | $10.7M | 11% |
| New Business Royalty Fees (2) | $7.9M | 8% |
| New Business Commissions (1) | $7.5M | 8% |
| Other | $3.7M | 4% |
| Initial Franchise Fees (2) | $1.6M | 2% |
